Are regimens containing rituximab effective in the initial treatment of Epstein–Barr virus-positive natural killer cell lymphoproliferative disease-associated hemophagocytic lymphohistiocytosis?

Title
Are regimens containing rituximab effective in the initial treatment of Epstein–Barr virus-positive natural killer cell lymphoproliferative disease-associated hemophagocytic lymphohistiocytosis?
Authors
Keywords
Natural Killer Cell, Mesilate, Collagen Disease, Hemophagocytic Lymphohistiocytosis, Gabexate
Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 98, Issue 3, Pages 375-377
Publisher
Springer Nature
Online
2013-08-21
DOI
10.1007/s12185-013-1419-4

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started